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ABSTRACT In skeletal muscle, excitation-contraction coupling involves a functional interaction between the ryanodine
receptor (RyR) and the dihydropyridine receptor (DHPR). The domain corresponding to Thr671-Leu690 of the II-III loop of the
skeletal DHPR 1-subunit is able to regulate RyR properties and calcium release from sarcoplasmic reticulum, whereas the
domain corresponding to Glu724-Pro760 antagonizes this effect. Two peptides, covering these sequences (peptide ASk and
CSk, respectively) were immobilized on polystyrene beads. We demonstrate that peptide ASk binds to the skeletal isoform of
RyR (RyR1) whereas peptide CSk does not. Using surface plasmon resonance detection, we show that 1) domain Thr
671-
Leu690 is the only sequence of the II-III loop binding with RyR1 and 2) the interaction of peptide ASk with RyR1 is not
modulated by Ca2 (pCa 9–2) nor by Mg2 (up to 10 mM). In contrast, this interaction is strongly potentiated by the
immunophilin FKBP12 (EC50  10 nM) and inhibited by both rapamycin (IC50  5 nM) and FK506. Peptide ASk induces a
300% increase of the opening probability of the RyR1 incorporated in lipid bilayer. Removal of FKBP12 from RyR1 completely
abolishes this effect of domain ASk on RyR1 channel behavior. These results demonstrate a direct interaction of the RyR1 with
the discrete domain of skeletal DHPR 1-subunit corresponding to Thr
671-Leu690 and show that the association of FKBP12
with RyR1 specifically modulates this interaction.
INTRODUCTION
Excitation-contraction (EC) coupling represents the differ-
ent steps leading to the contraction of the muscle cell
following the depolarization of its plasma membrane by the
action potential. Two proteins are responsible for this pro-
cess, the dihydropyridine receptor (DHPR), located in the
plasma membrane, and the ryanodine receptor (RyR), lo-
cated in the membrane of the sarcoplasmic reticulum (SR).
Although a number of similarities can be found between the
skeletal RyR type (RyR1) and the cardiac type (RyR2)
(Coronado et al., 1994; Otsu et al., 1990) or between the
skeletal DHPR and the cardiac type (Catterall, 1991; Camp-
bell and Giles, 1990; Mikami et al., 1989), it is widely
accepted that the molecular process of EC coupling strongly
differs in cardiac cells from skeletal cells (Rios and Pizarro,
1991; Rios et al., 1991; Schneider and Chandler, 1973). In
cardiac muscle cells, the Ca2 influx through the DHPR
directly induces the release of Ca2 from the SR via the
RyR2 by a calcium-induced calcium release process. In
contrast, in skeletal muscle cells, internal charge movement
within the DHPR, acting as a voltage sensor, induces a
conformational change of RyR1 that leads to its opening
and to the release of Ca2 from SR. This difference in EC
coupling mechanism between skeletal and cardiac muscle
cells has been used by a number of groups to define in more
details the molecular determinants of this process. It was
first shown by Tanabe and co-authors (1988) and by Knud-
son and co-authors (1989) that the 1S subunit of the DHPR
is at least partially responsible for EC coupling in skeletal
muscle. Next, the expression of various chimeric DHPR
1-subunit in dysgenic myotubes allowed the identification
of a 126-amino-acid domain, within the cytoplasmic II-III
loop of the 1-subunit, as being an important determinant
for skeletal type EC coupling (Tanabe et al., 1990a,b).
Meanwhile, the hypothesis of an interaction between RyR1
and the skeletal DHPR was reinforced by the demonstration
of their specific arrangement in the SR and plasma mem-
brane as well as by co-purification and co-immunoprecipi-
tation experiments (Block et al., 1988; Marty et al., 1994).
During the last few years, important efforts have been made
to determine the domains of both skeletal muscle DHPR and
RyR1 involved in this interaction. El-Hayek and collabora-
tors (El-Hayek et al., 1995; El-Hayek and Ikemoto, 1998)
identified two discrete domains of the II-III loop, termed
domain A (Thr671-Leu690) and domain C (Glu724-Pro760)
able to regulate Ca2 release from SR vesicles. Domain A
activates SR Ca2 release from and ryanodine binding to
SR vesicles whereas domain C antagonizes the effect of
domain A. The triggering effect of domain A on Ca release
from SR vesicles has since been confirmed by different
approaches (Dulhunty et al., 1999; Casarotto et al., 2000;
Lamb et al., 2000). Recently, Proenza and collaborators
(2000) have shown that expression, in dysgenic mice, of
1-subunit of skeletal DHPR carrying a scrambled sequence
of residues 681–690, part of domain A, led to the recovery
of the skeletal type of EC coupling, suggesting that domain
A is not directly responsible for EC coupling.
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In parallel, different studies have attempted to identify the
domain of RyR1 involved in the interaction with the II-III
loop of the DHPR. Molecular interaction studies have
shown that RyR1 residues Leu922-Asp1112 bind specifically
to the DHPR II-III loop (Leong and MacLennan, 1998a,b).
Meantime, functional studies of EC coupling in cells ex-
pressing RyR chimera, containing different regions of RyR1
and RyR2, lead to the identification of different domains of
RyR1, responsible for the interaction with the DHPR, cor-
responding to the residues 1303–1406 (Yamazawa et al.,
1997) and 1635–2636 (Nakai et al., 1998b), respectively.
In parallel, the number of proteins shown to interact with
the RyR and to modify its activity has considerably in-
creased (for review see MacKrill, 1999). One of these
proteins, the immunophilin FKBP12, is tightly associated
with RyR1. FKBP12 is a particularly interesting partner of
the RyR for two main reasons. First, its continuous associ-
ation with highly purified RyR1 and its high affinity for
RyR1 (Timerman et al., 1995; Jayaraman et al., 1992)
strongly suggest that FKBP12 is constitutively associated
with RyR1. Second, different isoforms of FKBP, FKBP12,
and FKBP12.6 seem to associate with the skeletal RyR1 and
the cardiac RyR2, respectively (Lam et al., 1995; Barg et al.,
1997), suggesting that this protein could partially contribute
to some of the difference in EC coupling mechanism be-
tween these two tissues. Although it has been demonstrated
that FKBP12 modifies the biophysical properties of RyR1
channel by stabilizing its full conductance state (Brillantes
et al., 1994; Ahern et al., 1997), the exact role of FKBP12
in the control of EC coupling remains to be elucidated.
In the present work, we have used molecular approaches
to study the binding of domain A (residue Thr671-Leu 690)
and domain C (Glu724-Pro760) of the 1S-subunit from the
DHPR, with RyR1, the skeletal isoform of RyR. We dem-
onstrate that only the skeletal form of the domain A binds to
RyR1 and is able to inhibit the binding of RyR1 with the
full-length II-III loop of the skeletal DHPR 1 subunit. We
also demonstrate that the association of FKBP12 with RyR1
is required for the interaction of the domain A with RyR1.
In support of this observation, we show that the modulation
of RyR1 channel activity by DHPR domain A is completely
abolished following FKBP12 depletion from RyR1.
MATERIALS AND METHODS
Isolation of SR vesicles
The skeletal heavy SR vesicles were prepared from rabbit leg and back
muscles by differential centrifugation, as previously described (Marty et
al., 1994; Anderson et al., 1989).
Purification of RyR
The skeletal SR vesicles were solubilized in the presence of CHAPS, and
RyR1 was purified by centrifugation of the solubilized proteins on a
sucrose density gradient (Lai et al., 1988). Purified RyR preparations were
stored in liquid nitrogen and their concentration determined using the Folin
method relative to bovine serum albumin.
Synthesis of peptides
Three peptides named peptide ASk and peptide ACd, corresponding to
residues Thr671-Lys690 and Thr795-Ala812 of the II-III loop of the skeletal
and cardiac DHPR 1-subunit, and peptide CSk corresponding to residues
Glu724-Pro760 of the skeletal DHPR 1-subunit were synthesized with an
exogenous biotin on the C-terminal amino acid.
The amino acid sequences of these peptides are as follows: peptide ASk,
TSAQKAKAEERKRRKMSRGL; peptide ACd, TSAQKEEEEEKERKKL-
ARTA; and peptide CSk, EFESNVNEVKDPYPSADFPGDDEEDEPEIPV.
Synthetic peptides were purified by chromatography, lyophilized, and
stored at20°C. Before use, the peptides were resuspended in sterile water
at a concentration of 10 mg/ml. Further dilutions were made in a buffer
containing 10 mM HEPES, pH 7.4, 150 mM NaCl (buffer T).
Expression and purification of the skeletal 1S
II-III loop
cDNA construction
The cDNA coding for the His-II-IIIS fusion protein was obtained by
subcloning the cDNA sequence of the II-IIIS loop into the His-pMR vector.
The 1S cDNA (GenBank X05921 rabbit 1S-subunit) was used as a
template for II-IIIS cDNA amplification, using the following oligonucleo-
tides: forward, 5-CATGCCATGGCAGTGGACAACCTGGCCGAGGC-
CGAGAGCCTGACT-3, and reverse, 5-GCTCTAGAGTCAGGTGGC-
GTTGACGATGCGGTGACACAGGACACG-3.
The PCR product was purified and subcloned into the NcoI and XbaI
sites of the pMR vector. This vector contains a minicistron for high-level
expression and a sequence coding for a polyhistidine tail fused to the amino
terminus of cloned genes (Arnaud et al., 1997).
Purification
Large BL21 bacteria cultures (400 ml) transformed with the pMR-II-IIIS-
His plasmid were grown at 37°C under agitation until an OD600 of 0.6 was
reached. Protein synthesis was induced by adding 1 mM isopropyl-1-1-
thio--D-galactopyranoside to the culture media for 4 h. The bacteria were
then pelleted (5000 rpm for 10 min on a Centrikon A 6.14 rotor, Kontron
Instruments, Paris, France) and resuspended in 10 ml of Tris-buffered
saline (TBS; 150 mM NaCl, 25 mM Tris, pH 7.4 with HCl) supplemented
with 1 mM benzaminide, 0.23 mM phenylmethylsulfonyl fluoride. The
cells were sonicated four times on ice for 30 s and the sample clarified by
centrifugation at 14,000  g (AM3815 rotor, Jouan MR22i) for 15 min.
The supernatant was kept on ice. Five milliliters of iminodiacetic acid
coupled onto Sepharose beads (Sigma Chemical Co., St. Louis, MO) were
added to a disposable polypropylene column leading to a final bed volume
of 2.5 ml. The column was washed with 3 vol of H2O, charged with 5 vol
of NiSO4 (50 mM), and equilibrated with 3 vol of loading buffer containing
(in mM): 40 imidazole, 500 NaCl, 50 Tris-HCl, pH 7.9. The sample was
then charged onto the column and washed with 30 ml of the same buffer.
The elution was performed with 15 ml of elution buffer (in mM: 200
imidazole, 500 NaCl, 50 Tris-HCl, pH 7.9). One-milliliter fractions were
collected during elution. Fractions were analyzed by electrophoresis on a
3–12% SDS-polyacrylamide gel, and protein bands were visualized by
staining with Coomassie Blue.
Immobilization on streptavidin
biomagnetic beads
One milligram of streptavidin Dynabeads (Dynal, Compie`gne, France),
washed three times with buffer T, were incubated for 30 min at room
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temperature in the presence of biotinyled peptide A (50 g/ml). The beads
were then washed three times with buffer T and incubated with purified
RyR (100 nM final concentration) for 1 h at room temperature. Purified
RyR that did not interact with the immobilized peptide was removed by
washing the beads twice with buffer T. The proteins bound to the immo-
bilized peptide were then eluted by boiling the beads for 5 min in 2.5%
SDS, separated on polyacrylamide gel, and analyzed by Western blot using
antibodies directed against the RyR.
Western blot analysis
Proteins were separated by electrophoresis on a 5–20% polyacrylamide gel
and transferred on Immobilon P sheet (4 h at 1 A). After saturation with
0.1% PBS-Tween and 4% milk (Biorad, Richmond, CA), the membrane
was incubated overnight at 4°C with anti-RyR antibodies (1/10,000 in
PBS-Tween). After several washes, the membrane was incubated for 3 h at
room temperature with goat anti-rabbit horseradish-peroxidase-conjugated
antibodies (1/40,000 in PBS-Tween, Jackson ABQ). The immunolabeling
was measured by chemiluminescence technique (Renaissance, NEN) using
x-ray films (hyperfilm max, Amersham, Pharmacia Biotech, Les Vlis,
France).
Real-time surface plasmon resonance
measurements
Real time surface plasmon resonance (SPR) experiments were performed
on a BIAcore biosensor system 1000 (Pharmacia Biosensor AB, Uppsala,
Sweden). All experiments were carried out at 25°C.
Peptides were immobilized on the sensor chip surface via an electro-
static bond (Kd  10
15 M) between their biotin and the surface-attached
streptavidin. Successful immobilization was evidenced by an increase in
resonance units of the order of 800 RU.
Recombinant II-III loop from the skeletal DHPR 1S-subunit was
immobilized on anti-His antibodies (Qiagen, Chatsworth, CA) covalently
immobilized on the sensor chip. Anti-His antibodies were immobilized on
the sensor chip via amino groups according to the manufacturer’s proce-
dure.
Purified RyR, previously dialyzed overnight at 4°C against a buffer
containing (in mM) 10 HEPES, 150 NaCl, pH 7.4, was injected at various
concentrations in similar buffer containing 0.005% polysorbate (running
buffer). Nonspecific interaction was measured by passing RyR over a
control surface saturated with biotin.
To measure the apparent affinity of the peptide ASk-RyR1 interaction,
RyR1 was incubated for 30 min at room temperature in the presence of
various concentrations of peptide ASk before injection on a sensor chip
coated with immobilized peptide ASk.
Experiments with FKBP12 or rapamycin
Purified RyR (5 nM) was incubated at room temperature for 45 min in the
presence of FKBP12 (human recombinant FKBP12, Sigma) or rapamycin
(Sigma).
Rapamycin (1 mM) was stored at20°C in ethanol:dimethylformamide
(8:2) and diluted before use in 10 mM HEPES, pH 7.4, 150 mM NaCl.
FKBP12 was diluted in distilled water and stored at 4°C.
Preparation of RyR1 depleted of FKBP12
To dissociate FKBP12 from the RyR, heavy sarcoplasmic reticulum ves-
icles were incubated in the presence of 5 fold molar excess of FK506, at
37°C for 30 min. FKBP12 depleted HSR vesicles were then collected by
centrifugation and used for the preparation of FKBP12 depleted RyR as
described by Barg et al. (1997). FK-506 was a generous gift from Fujisawa
Co. (Munich, Germany).
RyR Ca2 channel reconstitution and single-
channel recording analysis
Measurements of channel activity were carried out using solubilized RyR1
incorporated into planar lipid bilayer. The bilayers were formed using
phosphatidylethanolamine, phosphatidylserine, and L-phosphatidylcholine
in a ratio of 5:4:1 dissolved in n-decane up to the final lipid concentration
of 20 mg/ml (Herrmann-Frank et al., 1996). Bilayers were formed across
a 120- or 250-m aperture of a nolrene cap using a symmetrical buffer
solution (250 mM KCl, 100 MEGTA, 150 MCaCl2, 20 mM PIPES, pH
7.2). The chamber into which the small aliquot of solubilized RyR1 was
added is defined as the cis (cytoplasmic) side, whereas the other chamber,
labeled as the trans (luminal) side, was kept on ground potential. After
successful incorporation of RyR1 channel, free calcium concentration in
the cis chamber was adjusted to 10 M by addition of EGTA. At the end
of the measurement, ryanodine or ATP was applied to the cis chamber to
verify the orientation of the incorporated RyR1 being tested. Current
signals were filtered at 1 kHz using an 8-pole low-pass Bessel filter and
digitized at 3 kHz using an Axopatch 200 amplifier and pClamp 6.03
software (Axon Instruments, Foster City, CA). Total recording time in each
experiment was 5–10 min for any experimental condition tested. After
changing conditions, at least 5 min were allowed for equilibration, which
appeared to be enough to reach the new equilibrium of the parameters.
Single-channel measurements were carried out at 20–22°C; the free Ca2
concentration was calculated using the computer program and affinity
constants published by Fabiato (1988). Open probabilities were calculated
using the common 50% criteria with a medial dead zone of 5%. Current
amplitude distribution was analyzed using Origin (Microcal Software,
Northampton, MA). Values of the open probability and of the mean open
time are expressed as means  SE.
RESULTS
Binding of RyR1 on peptide ASk
Peptides corresponding to residues Thr671-Leu690 (peptide
ASk) and Glu
724-Pro760 (peptide CSk) of the 1-subunit of
the skeletal DHPR, and to the residues Thr795-Ala812 (pep-
tide ACd) of the cardiac DHPR were synthesized with a
biotin attached to the C-terminal end as described in Mate-
rials and Methods. To study their interaction with purified
RyR1, these peptides were immobilized on polystyrene
beads. Back titration of the unreacted peptide was per-
formed by ELISA technique, using antibodies directed
against biotin, and shows that, under the conditions used
(beads/peptide  50 w/w), all the biotinylated peptide was
immobilized on the beads (data not shown). The beads
coated with peptide ASk, peptide CSk, or peptide ACd were
then incubated with purified RyR1, washed with buffer, and
treated with SDS to elute proteins that reacted with the
peptide. These proteins were then analyzed by SDS-PAGE
or Western blot using antibodies directed against RyR1. Fig.
1 A shows the SDS-PAGE analysis of purified RyR1 prep-
aration and of the proteins present in the liquid phase at the
different steps of an experiment of interaction between
RyR1 and peptide ASk. Lane 2 shows the disappearance of
RyR1 in the medium after incubation with the beads, indi-
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cating the interaction of RyR1 with peptide ASk. Indeed,
RyR1 bound to the peptide is recovered after treatment of
the beads with SDS, as shown on lane 4. The different bands
appearing on lane 4, and in a smaller amount in lane 1, are
due to a proteolytic degradation of RyR1 caused both by the
incubation at room temperature and by the 5-min boiling
step necessary for the elution from the beads. Lane 3 shows
the absence of RyR1 in the washing solution, indicating that
the peptide ASk-RyR1 interaction is preserved during this
step. Absolutely no interaction of RyR1 with the naked
beads was observed (not shown). Fig. 1 B represents the
Western blot analysis of similar experiments performed
with either peptide ASk (left part), peptide ACd (middle
part), or peptide CSk (right part), immobilized on the beads
and incubated with RyR1. On this figure, the presence of
RyR1 was revealed by immunolabeling with specific anti-
bodies. These results clearly show that peptide ASk binds to
RyR1 (lane 4, left part) whereas, in the same conditions, no
RyR1 binding can be detected on peptide ACd or peptide
CSk (lane 4, middle and right part).
The interaction of peptide A with purified RyR1 was then
analyzed in greater detail using surface plasmon resonance
(SPR) detection. This technique measures the real-time as-
sociation and dissociation of molecules on a sensor surface.
For this purpose, equivalent amounts of peptide ASk, pep-
tide CSk, or peptide ACd were immobilized on a streptavi-
din-coated sensor chip, as described in Materials and Meth-
ods. Fig. 2 A (upper panel) represents the sensorgrams of
the interaction of RyR1 with peptide ASk (trace d), peptide
CSk (trace b), and peptide ACd (trace c). Histograms repre-
senting the average amplitude of these interactions are pre-
sented on Fig. 2 B. These results show that only peptide ASk
interacts with RyR1. This interaction was inhibited when
the purified RyR1 was incubated in presence of peptide ASk
(from 15 nM to 3 M) (Fig. 2 A, lower panel) before the
injection on immobilized peptide ASk. Half-inhibition
(IC50), reflecting the apparent affinity of peptide ASk for
RyR1 in solution, is observed at 130 nM peptide ASk.
In another set of experiments, the entire II-III loop of the
skeletal DHPR 1-subunit was immobilized on a sensor
FIGURE 1 Interaction of RyR1 with the different domains of 1S II-III loop. Peptide ASk and peptide ACd and peptide CSk were immobilized on magnetic
streptavidin beads as described in Materials and Methods. Purified RyR1 (100 nM in 10 mM HEPES, pH 7.4, 150 mM NaCl) was added to an equal amount
of peptide-coated beads. After incubation for 1 h at room temperature, the beads were washed three times with the same buffer and the bound proteins eluted
by boiling in the presence of SDS. (A) Coomassie blue-stained polyacrylamide gel (5–15%) of purified RyR1 preparations (1 g) and of the supernatant
at different steps of the experiment: lane 1, RyR1 preparation before incubation with peptide ASk-coated beads; lane 2, supernatant after incubation; lane
3, supernatant after the third wash; lane 4, supernatant after treatment of the beads with SDS. (B) Immunoblot analysis, with antibodies directed against
RyR1, of the supernatant at different steps of the interaction experiments: left part, RyR1 with peptide ASk; middle part, RyR1 with peptide ACd; right part,
RyR1 with peptide CSk. Lane 1, RyR1 preparation before incubation with peptide A coated beads; lane 2, supernatant after incubation; lane 3, supernatant
after the third wash; lane 4, supernatant after treatment of the beads with SDS.
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chip and tested for the interaction with RyR1. The II-III
loop was expressed as a His-tag fusion protein and immo-
bilized on the sensor chip via anti His-tag antibodies co-
valently immobilized on the sensor chip. Fig. 3 shows the
sensorgram of the interaction of purified RyR1 with immo-
bilized II-III loop (trace a). This interaction was inhibited
when RyR1 was incubated in the presence of peptide ASk
(traces b and c) before the injection on the immobilized
II-III loop. Incubation of RyR1 in presence of an excess of
peptide ASk (38 M, trace c) completely prevents its bind-
ing on the immobilized II-III. In contrast, incubation of
RyR1 in the presence of an excess of peptide CSk (38 M,
trace d) did not alter the interaction of RyR1 with the
immobilized II-III loop. The slight shift between traces a
NaCl, 0.005% polysorbate 20, running buffer) with biotin (trace a), peptide
CSk (trace b), peptide ACd (trace c), or peptide ASk (trace d). An equivalent
amount of each peptide was immobilized on different flow cell as de-
scribed in Materials and Methods. The shaded bar above the plot indicates
the injection of RyR1, and the empty bars denote running buffer alone.
(Lower panel) Dose-response relationship for inhibition of the binding of
RyR1 on immobilized peptide ASk by free peptide ASk. Purified RyR1 was
incubated in presence of peptide ASk (various concentrations in running
buffer) for 30 min at room temperature before injection in a flow cell
containing immobilized peptide ASk. Residual binding amplitude is ex-
pressed in percent of the binding amplitude measured when RyR1 was
incubated in the absence of peptide ASk. The continuous curve was ob-
tained by fitting the data according to the equation: residual binding 1/(1
 [ASk]/EC50). Opened and closed symbols represent experiments done
with two different RyR1 preparations. (B) Amplitude histogram of the
specific interaction signal of RyR1 (15 nM in running buffer) with peptide
ASk, peptide ACd, and peptide CSk. The amplitude of the binding signal was
measured after 5 min of interaction. Nonspecific binding was measured by
injection of RyR1 on flow cells containing immobilized biotin.
FIGURE 2 Real-time SPR detection of RyR1 binding on immobilized
domains of the II-III loop. (A, upper panel) SPR sensorgrams of the
interaction of purified RyR1 (6.5 nM in 10 mM HEPES, pH 7.4, 150 mM
FIGURE 3 Peptide ASk, but not peptide CSk, inhibits the binding of
RyR1 on the full-length II-III loop of skeletal DHPR 1S-subunit. Purified
RyR1 (200 nM in running buffer) was injected on the recombinant II-III
loop of the DHPR 1S-subunit immobilized on sensor chip (see Materials
and Methods). Before injection, purified RyR1 was incubated for 1 h in the
absence of (trace a) or presence of 380 nM peptide ASk (trace b), 38 M
peptide ASk (trace c), or 38 M peptide CSk (trace d). These curves are
representative of three different experiments. The shaded bar above the plot
indicates the injection of RyR1; empty bars denote running buffer alone.
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and d is due to the presence in the running buffer of the
peptide CSk but does not represent a significant change in
the binding signal amplitude.
Regulation of the binding of RyR1 on peptide ASk
We therefore examined the possible regulation of RyR1-
peptide ASk interaction by different effectors of the EC
coupling such as Ca2 and Mg2. Fig. 4 A represents the
amplitude of RyR1 binding on peptide ASk in presence of
increasing concentrations of free Ca2 and shows that the
interaction is not modified by changes in Ca2 concentra-
tion. No significant change of the association or dissociation
rates was observed in the range of free Ca2 concentrations
studied. Similarly, RyR1 binding on peptide ASk was not
modified by increasing Mg2 concentration from 0 to 10
mM (Fig. 4 B).
In a second set of experiments, we investigated the role of
the FKBP12 in the regulation of RyR1-peptide ASk inter-
action. Two drugs, rapamycin and FK506, are known to
bind to FKPB12 and induce its dissociation from RyR1.
Using the SPR approach, we measured RyR1-peptide ASk
interaction after incubation of RyR1 with rapamycin or with
FKBP12. The results presented on Fig. 5 show that prein-
cubation of RyR1 with rapamycin (open circles) induces an
inhibition of its binding on peptide ASk (IC50 in the low
nanomolar range). Similar results were obtained using
FK506 instead of rapamycin (not shown). Full binding
inhibition was not reached, presumably because these drugs
are unable to remove all the RyR1-associated FKBP12.
Conversely, preincubation of RyR1 with increasing concen-
trations of recombinant FKBP12 (Fig. 5, closed circles)
potentiates its binding on peptide ASk (EC50 10 nM). This
effect of FKBP12 was completely abolished when FKBP12
was incubated with rapamycin before the incubation with
RyR1 (data not shown). These results clearly demonstrate
the involvement of FKBP12 in the formation of the inter-
action RyR1-peptide ASk. The effect of FKBP12 addition to
the purified RyR1 suggests that the purified RyR1 prepara-
tion may contain RyR1 molecules associated with 0, 1, 2, 3,
or 4 FKBP12, in agreement with the results obtained by
different groups (Jayaraman et al., 1992; Timerman et al.,
1995). These results suggest that FKBP12 may serve as a
link between domain A of the DHPR 1-subunit and RyR1.
To test this hypothesis, we investigated the binding of
FIGURE 4 RyR1-peptide ASk interaction is independent of the Ca
2 and
Mg2 concentrations. Purified RyR1, 5 nM in 10 mM HEPES, pH 7.4, 1
mM EDTA, 150 mM NaCl, 0.005% polysorbate 20, and various CaCl2
concentrations (A) or in 10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005%
polysorbate 20, and various MgCl2 concentrations (B) was injected into a
flow cell containing immobilized peptide ASk. The amplitude of the spe-
cific binding signal was measured after 5 min. Each point represents the
average  SD of at least four experiments.
FIGURE 5 Effect of FKBP12 and rapamycin on the binding of RyR1 on
peptide ASk. RyR1 (5 nM in running buffer) was incubated for 45 minutes
at room temperature in the presence of various concentrations of rapamycin
(E) or human recombinant FKBP12 (F) and then injected into a flow cell
containing immobilized peptide ASk. The amplitude of the specific binding
signal was measured after 5 min. Each point represents the average value
SD of at least seven experiments.
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FKBP12 on peptide ASk. Recombinant FKBP12 (up to 1
M) was injected on a sensor chip coated with peptide ASk.
Because of the low molecular weight of FKBP12, which
could result in a small binding signal, anti-FKBP12 anti-
bodies were injected just after recombinant FKBP12. No
binding signal was observed after injection either of
FKBP12 or of the antibodies (not shown). The effect of
FKBP12 is therefore not mediated through a direct interac-
tion between FKBP12 and domain A of the DHPR.
Effect of peptide ASk on RyR1 Ca
2 channel
behavior
To investigate the functional aspect of the interaction RyR1-
peptide ASk, we studied the effect of peptide ASk on the
behavior of purified RyR1 reconstituted in artificial lipid
bilayer as described in Materials and Methods. Fig. 6 A
represents the single-channel recording of purified RyR1
incorporated in lipid bilayer. Sixty to eighty percent of the
reconstituted channels were ryanodine sensitive and pre-
sented only two peaks on the current histogram. This last
criterion is a widely accepted sign that the RyR1 channel is
in its native state associated to all four FKBP12 molecules.
The addition of peptide ASk to the cis chamber induces an
increase of the open probability of RyR from 0.143 0.052
(SE, n  8) to 0.482  0.131 (SE, n  5) in the presence
of 26 M peptide ASk, whereas no significant change of the
mean open time was observed. This activation by peptide
ASk was independent of the holding potential and was
observed at positive or negative holding potential equally.
In a second set of experiments (Fig. 6 B), we measured the
influence of FKBP12 removal on the effect of peptide ASk
on RyR1 behavior. For this purpose, RyR1 was purified
from SR vesicles depleted of FKBP12 by treatment with
FK506 as described in Materials and Methods. The effi-
ciency of the depletion is objectified on the histograms
presented on Fig. 5 B by the fact that depleted RyR1 Ca2
channel opens predominantly to subconductance levels, in
contrast to what is observed for the nondepleted RyR1 (Fig.
6 A). This characteristic of FKBP12-depleted RyR1 was
previously described by several groups (Brillantes et al.,
1994; Ahern et al., 1997) and currently represents the most
established electrophysiological effect of FKBP12 deple-
tion. The presence of five peaks on the current histogram
suggests that FKBP12 depletion is complete on the recorded
channel. Full depletion was, however, not reached on each
channel, and those recordings that did not possess the five
characteristic conductances were discarded. Fig. 6 B shows
that, in these conditions, the addition of peptide ASk (up to
26 M) has no effect on the channel behavior of FKBP12-
stripped RyR1, with Po values being 0.312  0.178 (SE,
n  5) and 0.327  0.158 (SE, n  6) in the control and in
the presence of 26 M peptide ASk, respectively. No change
in the pattern of subconductance levels of stripped RyR1
was observed in the absence or the presence of peptide ASk
(Fig. 6 B). To check that normal RyR as well as FKBP12-
depleted RyR is still responsive to regular effectors, ATP
was added after the addition of the peptide ASk. Traces c
and f and corresponding histograms show a clear activation
of the normal RyR and the FKBP12 depleted RyR by
addition of ATP. Similar effects of Ca2 and ryanodine
were also observed on normal and FKBP12-depleted RYR1
(not shown). To test the reversibility of the effect of FK506
on the interaction of RyR1 and peptide ASk, FKBP12-
depleted RyR1 was incubated in presence of an excess of
recombinant FKBP12 before injection of the peptide ASk.
After incubation with FKBP12, RyR1 channel behavior is
again characterized by predominant single opening state
(not shown). Addition of peptide ASk on the reconstituted
FKBP12-RyR1 complex induces an increase of the open
probability of RyR1 from 0.178 (n  3) to 0.496 (n  3) in
the presence of 26 M peptide ASk, clearly demonstrating
the reversibility of the FKBP12 depletion effect on RyR1-
peptide ASk interaction.
We also tested the effect of peptide ACd on RyR1-
FKBP12 activity. Under conditions similar to those de-
scribed for Fig. 6 A, addition of peptide ACd (up to 26 M)
to the cis chamber did not induce any modification of the
RyR1 behavior: Po values were 0.223  0.103 (SE, n  6)
for the control conditions and 0.229 0.124 (SE, n  4) in
the presence of 26 M peptide ACd (data not shown).
DISCUSSION
Several studies have previously shown that the cytoplasmic
loop linking the repeat II and III of the DHPR 1-subunit
plays a critical role in the control of the EC coupling process
(Tanabe et al., 1990b). This region of the DHPR therefore
represents a good candidate for interactions with the RyR1.
Two domains of this loop, domain A and domain C, respec-
tively, have been postulated to be involved in the control of
EC coupling. However, the roles of each of these domains
as well as the way they interact with RyR1 are still debated.
Domain A activates Ca2 release from SR vesicles and
increases RyR1 channel open probability whereas domain C
itself does not affect Ca2 release but is able to antagonize
the effect of domain A. On the other hand, electrophysio-
logical studies of the EC coupling have shown that domain
C is essential in determining the type of EC coupling
whereas domain A does not seem to be directly involved in
this process.
In this work, we studied the direct interaction of each of
these domains with RyR1 and illustrate several new points.
First, the domain of the skeletal DHPR 1S-subunit encom-
passing residues Thr671-Leu690 (domain ASk) binds to
RyR1. Under the same conditions, the corresponding do-
main of the cardiac DHPR 1-subunit (domain ACd, resi-
dues Thr795-Ala812) does not show any interaction with
RyR1. Second, the domain of the skeletal DHPR 1S-
subunit encompassing residues Glu724-Pro760 (domain CSk)
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does not bind to RyR1. Third, domain ASk but not domain
CSk completely inhibits the interaction of RyR1 with the
full-length II-III loop of the skeletal DHPR 1S-subunit.
Fourth, the binding of domain ASk to RyR1 is strongly
dependent on the interaction of RyR1 with the immunophi-
lin FKBP12. The association RyR1 domain ASk is selec-
tively antagonized by the immunosuppressive drugs rapa-
mycin and FK506 and potentiated by addition of
recombinant FKBP12. We also show that Ca2 or Mg2
does not regulate the association between domain ASk and
RyR1. Finally, the interaction of domain ASk with RyR1
induces a modification of the RyR1 Ca2 channel behavior
characterized by an increase of the open probability, an
effect that is absent when FKBP12 is dissociated from the
RyR1.
From these results we can conclude that domain A rep-
resents the major binding site, if not the only one, of the
II-III loop of the 1S-subunit of the DHPR to RyR1. This
interaction is strictly dependent of the DHPR isoform be-
cause no interaction of the corresponding domain of the
cardiac DHPR with RyR1 was observed. The fact that Ca2
or Mg2 does not modulate this interaction suggests that
these proteins could be constitutively linked under physio-
logical conditions.
FKBP12, a member of the immunophilins family, has
been shown to be tightly associated with RyR1 (Kd in the
range of 6 nM), with a stoichiometry of four FKBP12 per
tetramer of RyR1 (Timerman et al., 1993. 1995). The im-
munosuppressive drugs rapamycin and FK506 induce a
dissociation of FKBP from RyR. Several groups have
shown that FKBP12 modifies the calcium channel gating
behavior of RyR1, suggesting that FKBP12 plays a role in
the control of the conformational state of the ryanodine
receptor (Brillantes et al., 1994; Barg et al., 1997; Ahern et
al., 1997). More recently Dulhunty and collaborators (1999)
have shown that the ability of peptide ASk to activate RyR1
is reduced when SR membrane vesicles are treated with
rapamycin. We show here that nanomolar concentrations of
FKBP12 strongly potentiate the association of skeletal
DHPR domain A with RyR1, whereas rapamycin or FK506
inhibits this interaction. Because no direct binding of the
FKBP12 on domain ASk was observed, the inhibition of the
RyR1-domain A interaction by rapamycin is likely to be due
to allosteric changes of RyR1 initiated by FKBP12 removal.
This suggests that FKBP12 stabilizes RyR1 in a conforma-
tional state that allows its interaction with the domain A.
Using purified RyR1 incorporated in artificial bilayer, we
show that the complex RyR1-domain ASk is characterized
by a higher opening probability of the RyR1 Ca2 channel.
In complete coherence with what was observed for the
interaction of RyR1-domain A, the effect of domain ASk on
the open probability of RyR1 was lost when the FKBP12 is
dissociated from the RyR1.
These results clearly demonstrate the important role of
FKBP12 in the formation of the protein complex that in-
volves RyR1 and the skeletal DHPR, which is a prerequisite
for the establishment of EC coupling in skeletal muscle
cells. Interestingly, Lamb and Stephenson (1996) have
shown that, in rat skinned skeletal myofibrils, FK506 and
rapamycin led to a progressive loss in the depolarization-
induced Ca2 release from SR although they had no effect
on Ca2 release induced by caffeine. However, skeletal
muscle cells of mice lacking FKBP12 do not show signif-
icant histological or electron-microscopy-detectable abnor-
malities (Shou et al., 1998). Although these results question
the exact role of FKBP12 in the skeletal muscle cell, they
might suggest that FKBP12 as well as the interaction of
domain A with RyR1 are involved in a fine control of the
EC coupling process during the long-term evolution of the
skeletal muscle cells.
Domain C has been shown to antagonize the effect of
domain A on depolarization-induced Ca release from SR
vesicle or in skinned fiber but is not able to modify, by
itself, the Ca release induced by caffeine (Lamb et al., 2000;
Saiki et al., 1999; El-Hayek et al., 1995). Electrophysiolog-
ical studies have shown that domain C is important for the
control of EC coupling (Nakai et al., 1998a). Our results,
showing that this domain does not interact directly with
RyR1, prompt us to propose that the domain C regulates
RyR1 by interacting with another protein of the complex or
with another domain of the DHPR. This hypothesis could
explain the apparent discrepancies in the identification of
the domain of RyR1 involved in the interaction with the
II-III loop and those involved in the regulation of EC
coupling. Indeed, molecular interactions studies have shown
that residues 922-1112 of RyR1 bind to the entire II-III loop
of the 1S DHPR (Leong and MacLennan, 1998), whereas
electrophysiological studies have identified the residues
FIGURE 6 Effect of peptide ASk on the RyR channel activity and effect of the depletion of FKBP12 from the channel complex. Control and
FKBP12-depleted solubilized RyR1 Ca2 channel complex was incorporated into a lipid bilayer and channel current measured under voltage clamp
conditions, as described in Materials and Methods. Holding potential was 60 mV: cis side [Ca2] was 10 M, and charge carrier was K (250 mM cis
side). Channel openings are represented by upward deflections. Current traces were analyzed for Po, mean open time and amplitude distribution. (A)
Representative current trace were recorded in the absence of peptide ASk (a, serves as a control) and in the presence of 26 M peptide ASk (b) or 26 M
of peptide ASk and 2 mM ATP (c). Closed states of the channel are marked on the left margin and calibration current bar exhibited on the bottom of the
panel. Current-amplitude distributions obtained under similar conditions are shown in the lower part of the upper panel. (B) Representative current traces
recorded in the absence of peptide ASk (d, serves as control) and in the presence of 26 M peptide ASk (e) or 26 M peptide ASk and 2 mM ATP (f) using
FKBP12-depleted RyR1 incorporated into the lipid bilayer. Current-amplitude distributions obtained under identical conditions are shown in the lower part
of this panel.
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1303–1406 (Yamazawa et al., 1997) or 1635–2636 (Nakai
et al., 1998b) as being involved in the control of EC cou-
pling. Therefore domain ASk-RyR1 interaction could in-
volve the residues 922-1112 of RyR1 whereas domain C
could interact with another domain of the DHPR, or another
protein, itself interacting with the residues 1303–1406 or
1635–2636 of RyR1. Other domains of the 1S DHPR
subunit such as the C-terminal domain (Slavik et al., 1997)
and the III-IV cytoplasmic loop (Leong and MacLennan,
1998b), have been shown to regulate or to interact directly
with RyR1 and could therefore represent a potential inter-
acting site with domain C. Recently, Avila and collaborators
(2001) have shown that a single mutation (I4898T) in a
putative intra-luminal region of RyR1, different from the
RyR1 region previously shown to be important for EC
coupling, completely abolishes the EC coupling in skeletal
muscle cell. These results strongly suggest that several
domains of the RyR1, as well as of the DHPR, could control
the fine-tuning of the EC process in skeletal muscle.
By allowing the study of the interaction step per se
between different domains of the DHPR and RyR, the
different approaches developed in the present work should
be very useful in determining the specific role of these
different domains in the formation and the regulation of the
RyR-DHPR complex.
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